ERBB2 and breast cancer: Of all the subtypes of breast cancer, the most aggressive one is TNBC, which confers a much poorer prognosis, higher rates of recurrence, and fewer treatment options compared to hormone receptor-positive or HER2-enriched subtypes [1,4].